MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis

Nature Medicine

Volumn 16, Issue 8, 2010, Pages 909-914

  Anand, Sudarshan ^a   Majeti, Bharat K ^a   Acevedo, Lisette M ^a   Murphy, Eric A ^a   Mukthavaram, Rajesh ^a   Scheppke, Lea ^a   Huang, Miller ^a   Shields, David J ^a   Lindquist, Jeffrey N ^a   Lapinski, Philip E ^b   King, Philip D ^b   Weis, Sara M ^a   Cheresh, David A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE PROTEIN; MICRORNA; MICRORNA 132; P120RASGAP PROTEIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM; GENE DELETION; HEMANGIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; RETINA BLOOD VESSEL; RETINA DEVELOPMENT; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION; WILD TYPE;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL PROLIFERATION; CELLS, CULTURED; DRUG EVALUATION, PRECLINICAL; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; MICE; MICE, INBRED C57BL; MICRORNAS; NEOVASCULARIZATION, PATHOLOGIC; P120 GTPASE ACTIVATING PROTEIN; RETINAL ARTERY; RNA INTERFERENCE; RNA, SMALL INTERFERING; UP-REGULATION;

MUS;

EID: 77955384669     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2186     Document Type: Article

References (40)

1. Murphy, E.A. et al. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc. Natl. Acad. Sci. USA 105, 9343-9348 (2008).
2. Hobson, B. & Denekamp, J. Endothelial proliferation in tumours and normal tissues: continuous labelling studies. Br. J. Cancer 49, 405-413 (1984).
3. Folkman, J. The role of angiogenesis in tumor growth. Semin. Cancer Biol. 3, 65-71 (1992).
4. Fish, J.E. & Srivastava, D. MicroRNAs: opening a new vein in angiogenesis research. Sci. Signal. 2, pe1 (2009).
5. Lindquist, J.N., Cheresh, D.A. & Snyder, E.Y. Derivation of vasculature from embryonic stem cells. Curr. Protoc. Stem Cell Biol. 12, 1.1F.9.1-1.1F.9.6 (2010).
6. Kelly, M.A. & Hirschi, K.K. Signaling hierarchy regulating human endothelial cell development. Arterioscler. Thromb. Vasc. Biol. 29, 718-724 (2009).
7. Nudelman, A.S. et al. Neuronal activity rapidly induces transcription of the CREBregulated microRNA-132, in vivo. Hippocampus 20, 492-498 (2010).
8. Vo, N. et al. A cAMP-response element binding protein-induced microRNA regulates neuronal morphogenesis. Proc. Natl. Acad. Sci. USA 102, 16426-16431 (2005).
9. Mayo, L.D., Kessler, K.M., Pincheira, R., Warren, R.S. & Donner, D.B. Vascular endothelial cell growth factor activates CRE-binding protein by signaling through the KDR receptor tyrosine kinase. J. Biol. Chem. 276, 25184-25189 (2001).
10. Tan, Y. et al. FGF and stress regulate CREB and ATF-1 via a pathway involving p38 MAP kinase and MAPKAP kinase-2. EMBO J. 15, 4629-4642 (1996).
11. Kenneth, T.E. & Kertes, P.J. Ranibizumab in neovascular age-related macular degeneration. Clin. Interv. Aging 1, 451-466 (2006).
12. Gragoudas, E.S., Adamis, A.P., Cunningham, E.T. Jr., Feinsod, M. & Guyer, D.R. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. 351, 2805-2816 (2004).
13. Griffiths-Jones, S., Grocock, R.J., van Dongen, S., Bateman, A. & Enright, A.J. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 34, D140-D144 (2006).
14. Lewis, B.P., Burge, C.B. & Bartel, D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120, 15-20 (2005).
15. Krek, A. et al. Combinatorial microRNA target predictions. Nat. Genet. 37, 495-500 (2005).
16. Rehmsmeier, M., Steffen, P., Hochsmann, M. & Giegerich, R. Fast and effective prediction of microRNA/target duplexes. RNA 10, 1507-1517 (2004).
17. Bartel, D.P. MicroRNAs: target recognition and regulatory functions. Cell 136, 215-233 (2009).
18. Hoshino, M., Kawakita, M. & Hattori, S. Characterization of a factor that stimulates hydrolysis of GTP bound to ras gene product p21 (GTPase-activating protein) and correlation of its activity to cell density. Mol. Cell. Biol. 8, 4169-4173 (1988).
19. McCormick, F. ras GTPase activating protein: signal transmitter and signal terminator. Cell 56, 5-8 (1989).
20. Lapinski, P.E. et al. Generation of mice with a conditional allele of the p120 Ras GTPase-activating protein. Genesis 45, 762-767 (2007).
21. Henkemeyer, M. et al. Vascular system defects and neuronal apoptosis in mice lacking ras GTPase-activating protein. Nature 377, 695-701 (1995).
22. Boon, L.M., Mulliken, J.B. & Vikkula, M. RASA1: variable phenotype with capillary and arteriovenous malformations. Curr. Opin. Genet. Dev. 15, 265-269 (2005).
23. Eerola, I. et al. Capillary malformation-arteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations. Am. J. Hum. Genet. 73, 1240-1249 (2003).
24. Hershkovitz, D., Bercovich, D., Sprecher, E. & Lapidot, M. RASA1 mutations may cause hereditary capillary malformations without arteriovenous malformations. Br. J. Dermatol. 158, 1035-1040 (2008).
25. Hood, J.D. et al. Tumor regression by targeted gene delivery to the neovasculature. Science 296, 2404-2407 (2002).
26. Fish, J.E. et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev. Cell 15, 272-284 (2008).
27. Harris, T.A., Yamakuchi, M., Ferlito, M., Mendell, J.T. & Lowenstein, C.J. MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc. Natl. Acad. Sci. USA 105, 1516-1521 (2008).
28. Wang, S. et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev. Cell 15, 261-271 (2008).
29. Würdinger, T. et al. miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells. Cancer Cell 14, 382-393 (2008).
30. Bonauer, A. et al. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 324, 1710-1713 (2009).
31. Komada, M. & Kitamura, N. The Hrs/STAM complex in the downregulation of receptor tyrosine kinases. J. Biochem. 137, 1-8 (2005).
32. Kulkarni, S.V., Gish, G., van der Geer, P., Henkemeyer, M. & Pawson, T. Role of p120 Ras-GAP in directed cell movement. J. Cell Biol. 149, 457-470 (2000).
33. Meadows, K.N., Bryant, P., Vincent, P.A. & Pumiglia, K.M. Activated Ras induces a proangiogenic phenotype in primary endothelial cells. Oncogene 23, 192-200 (2004).
34. Bergers, G. & Hanahan, D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8, 592-603 (2008).
35. Munoz, R. et al. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res. 66, 3386-3391 (2006).
36. Koh, W., Stratman, A.N., Sacharidou, A. & Davis, G.E. In vitro three dimensional collagen matrix models of endothelial lumen formation during vasculogenesis and angiogenesis. Methods Enzymol. 443, 83-101 (2008).
37. Pena, J.T. et al. miRNA in situ hybridization in formaldehyde and EDC-fixed tissues. Nat. Methods 6, 139-141 (2009).
38. Scheppke, L. et al. Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits. J. Clin. Invest. 118, 2337-2346 (2008).
39. Weis, S., Cui, J., Barnes, L. & Cheresh, D. Endothelial barrier disruption by VEGFmediated Src activity potentiates tumor cell extravasation and metastasis. J. Cell Biol. 167, 223-229 (2004).
40. Desgrosellier, J.S. et al. An integrin?v?3-c-Src oncogenic unit promotes anchorageindependence and tumor progression. Nat. Med. 15, 1163-1169 (2009).